LGND  valuation analysis

Name: Ligand Pharmaceuticals Incorporated
Description: Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Feb 17, 2022
Market cap: $1.83B (1097th)
Sales(TTM): $277.13M (1333rd)
Earnings(TTM): $57.59M (1101st)

FFER: 1.66*
Actual price: $109.38
* Earnings were reported May 02, 2022 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2022-03-17
Price & Estimates
Sales & Earnings history (TTM)
  • Ligand Pharmaceuticals Incorporated's earnings increased from -$2.98M to $57.59M in the last year.
  • Ligand Pharmaceuticals Incorporated's sales grew by 48.7% ($186.42M to $277.13M) over one year against a market average growth of 24.0%.
Earnings / MarketCap
Ligand Pharmaceuticals Incorporated
"Biotechnology" industry
Sales / MarketCap
Ligand Pharmaceuticals Incorporated
"Biotechnology" industry
Book / MarketCap
Ligand Pharmaceuticals Incorporated
"Biotechnology" industry
Equity / Assets
Ligand Pharmaceuticals Incorporated
"Biotechnology" industry